Skip to main content
Report File
Date Issued
Submitting OIG
Amtrak (National Railroad Passenger Corporation) OIG
Other Participating OIGs
Amtrak (National Railroad Passenger Corporation) OIG
Agencies Reviewed/Investigated
Amtrak (National Railroad Passenger Corporation)
Report Number
OIG-WS-2023-301
Report Description

An Amtrak Maintainer based in Newark, New Jersey, and a Trainer based in Sunnyside, New York, were terminated after their disciplinary hearings on October 4, 2022. The two former employees conspired with another employee, Keith Kovaleski, to sell misbranded and unapproved new drugs. The Maintainer violated company policies by ordering misbranded and/or unapproved new drugs from Kovaleski’s company, All American Peptide (AAP), and by accepting shipments of these products on behalf of Kovaleski. The Trainer violated company policies by regularly ordering misbranded and/or unapproved new drugs from AAP and reselling them to the public. Kovaleski, an Assistant Foreman based in New York, is currently awaiting sentencing after pleading guilty on March 21, 2022, to selling misbranded and unapproved new drugs. The two former employees are ineligible for rehire.

Report Type
Investigation
Location

Sunnyside, NY
United States

Questioned Costs
$0
Funds for Better Use
$0

Amtrak (National Railroad Passenger Corporation) OIG

United States